面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经2月26日讯（记者 何凡）受首款商业化产品销售市场扩张等因素影响，专注于自免疾病等领域 的智翔金泰-U（688443.SH）2025年总营收同比大幅增长，净亏损同比收窄超30%，但公司距离盈利仍 有不小差距。 今日晚间，智翔金泰发布2025年业绩快报，去年，智翔金泰实现营业总收入约2.31亿元，与2024年同期 相比增长666.65%；实现归母净亏损5.36亿元，亏损同比收窄32.74%；扣非归母净亏损5.79亿元，亏损 同比收窄27.99%。但同时这也意味着，截至2025年末，公司仍未盈利，数据显示，2021年—2025年， 智翔金泰5年时间中净亏损已超30亿元。 报告期末，公司总资产为29.93亿元，较上年同期下降4.87%；归属于母公司的所有者权益为15.84亿 元，较上年同期下降25.49%。 对于营收增长的原因，公司表示主要在于，其一，报告期内公司进一步推动首款商业化产品 ...

格隆汇2月26日丨智翔金泰(688443.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入2.31亿 元，与去年同期相比增长666.65%；实现归属于母公司所有者的净利润-5.36亿元，与去年同期相比亏损 收窄32.74%；实现归属于母公司所有者的扣除非经常性损益的净利润-5.79亿元，与去年同期相比亏损 收窄27.99%。 报告期内，公司营业收入较上年同期增加666.65%、营业利润较上年同期亏损收窄33.57%、利润总额较 上年同期亏损收窄32.74%、归属于母公司所有者的净利润较上年同期亏损收窄32.74%，主要系报告期 内公司进一步推动首款商业化产品赛立奇单抗注射液（金立希®）销售市场扩张，产品销售收入较上年 同期稳步增长；同时，GR1803注射液授权许可及商业化协议的合同履约义务所对应的授权许可收入金 额较大，对公司当期净利润产生了积极影响。 ...

报告期内，公司营业收入较上年同期增加666.65%、营业利润较上年同期亏损收窄33.57%、利润总额较 上年同期亏损收窄32.74%、归属于母公司所有者的净利润较上年同期亏损收窄32.74%，主要系报告期 内公司进一步推动首款商业化产品赛立奇单抗注射液（金立希®）销售市场扩张，产品销售收入较上年 同期稳步增长；同时，GR1803注射液授权许可及商业化协议的合同履约义务所对应的授权许可收入金 额较大，对公司当期净利润产生了积极影响。 格隆汇2月26日丨智翔金泰(688443.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入2.31亿 元，与去年同期相比增长666.65%；实现归属于母公司所有者的净利润-5.36亿元，与去年同期相比亏损 收窄32.74%；实现归属于母公司所有者的扣除非经常性损益的净利润-5.79亿元，与去年同期相比亏损 收窄27.99%。 ...

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (referred to as "Zhixiang Jintai") expects significant revenue growth for the year 2025, while still projecting a net loss, albeit with a reduced loss compared to the previous year [1][2]. Financial Performance - The company forecasts a revenue of between 209 million to 251 million yuan for 2025, representing an increase of 179 million to 221 million yuan year-on-year, which translates to a substantial growth of 595.96% to 733.62% [1]. - The projected net loss attributable to the parent company for 2025 is estimated to be between 481 million to 587 million yuan, which is a year-on-year reduction in loss of 26.32% to 39.71% [1]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be between 524 million to 630 million yuan, with a year-on-year loss reduction of 21.62% to 34.90% [1]. Research and Development - The company anticipates R&D expenses for 2025 to be between 425 million to 520 million yuan, reflecting a decrease of 14.77% to 30.27% compared to the previous year [1]. - The company maintains a high level of R&D investment as multiple products enter clinical research and core products reach critical clinical trial phases [2]. - The absence of share-based payment expenses in 2025, due to the completion of the stock incentive plan for the core team in 2024, contributes to the reduction in overall expenses [2].

Core Viewpoint - Zhixiang Jintai (688443.SH) forecasts a net loss attributable to shareholders of the parent company for 2025, estimated between -480.64 million to -587.45 million yuan, representing a year-on-year reduction in losses by 209.83 million to 316.64 million yuan, or a decrease of 26.32% to 39.71% compared to the previous year [1] Group 1: Financial Performance - The company's operating revenue has significantly increased compared to the same period last year, primarily due to steady sales growth of its first commercial product, Saliqi monoclonal antibody injection (Jinlixi®), and revenue from the licensing agreement for GR1803 injection [1] - The forecasted net loss for 2025 indicates a substantial improvement in financial performance compared to the previous year [1] Group 2: Research and Development - The company continues to focus on original innovation and efficiently advancing the progress of various research projects, with multiple products entering clinical research and core products entering critical clinical trial phases [1] - The company maintains a high level of R&D investment in its ongoing projects, reflecting its commitment to innovation [1] - The stock incentive plan implemented for the core team in 2022 will expire in 2024, resulting in a reduction of corresponding expenses in 2025 [1]

2025年12月7日，国家医疗保障局正式公布《国家基本医疗保险、生育保险和工伤保险药品目录（2025 年）》（以下简称"国家医保目录"）。重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"）宣 布，其自主研发的1类生物创新药——赛立奇单抗注射液（金立希®）成功纳入国家医保目录。新版国 家医保目录将于2026年1月1日起正式实施。 源头创新，国产原研突破垄断 作为一家专注于全链条抗体药物研发与产业化的创新型生物制药企业，智翔金泰始终坚持以科技创新为 核心驱动力，聚焦未被满足的重大临床需求，致力于为患者提供高质量、可负担的治疗选择。 赛立奇单抗注射液是智翔金泰基于独有的双载体噬菌体呈现技术平台研发的重组全人源抗IL-17A单克隆 抗体。该药物通过特异性结合血清中的IL-17A细胞因子，阻断IL-17A与IL-17RA的结合，抑制炎症的发 生和疾病的发展。作为我国首款全人源抗IL-17A单克隆抗体，赛立奇单抗自2024年8月获批上市以来， 已陆续获批用于治疗中、重度斑块状银屑病和强直性脊柱炎（放射学阳性中轴型脊柱关节炎）两大适应 症，打破了外资药企在该靶点治疗药物的垄断局面，为中国患者提供了与国际水平接轨的高质 ...

Core Insights - A-share companies reported stable growth in 2024, with total revenue reaching 71.92 trillion yuan and net profit at 5.21 trillion yuan, with 75% of companies profitable and 48% showing year-on-year profit growth [1] Group 1: Industry Performance - The agriculture, forestry, animal husbandry, and fishery sectors saw significant profit growth, with a net profit increase of 1447%, primarily due to falling feed prices benefiting livestock companies [1] - The electronic and non-bank financial sectors led revenue growth, each with approximately 17% increase [1] Group 2: Company Highlights - 117 companies achieved revenue exceeding 100 billion yuan, marking a historical high, with 7 companies surpassing 1 trillion yuan in revenue [1] - BYD's revenue reached 777.1 billion yuan in 2024, a 29% increase, surpassing Tesla's annual revenue for the first time [2] - 65 companies doubled their revenue in 2024, with Zhixiang Jintai leading at a 2384.1% increase due to a newly approved drug [3] Group 3: Profitability - 77 companies reported net profits exceeding 10 billion yuan, with 10 companies surpassing 100 billion yuan, mainly in the banking and insurance sectors [6] - Zhengdan Co. achieved a net profit growth rate of nearly 120 times, driven by soaring prices of its main product [6][7] Group 4: R&D Investment - A-share companies collectively invested 1.6 trillion yuan in R&D in 2024, with 22 companies exceeding 10 billion yuan in R&D spending [8] - BYD led R&D investment with 54.16 billion yuan, contributing to significant technological advancements [8]